Amanda King ND is a nutritional therapist, naturopathic practitioner, and author of Metabolic Drugs for Cancer (co-written with Dr. Hari Kuhan). She also writes The Metabolic Nutritionist on Substack—followed by 30,000+ subscribers—where she breaks down off-label oncology drugs, supplements, and metabolic approaches to cancer care in clear, practical language. In this episode, Dr. King joins Dr. Michael Karlfeldt to explain why “cancer is a disease of metabolism” is more than a slogan—and how understanding metabolic weaknesses can empower smarter, more personalized integrative strategies.
You’ll hear how repurposed medications can target cancer’s metabolic pathways (glucose, mitochondria, inflammatory signaling, and more), and why personalization matters more than internet protocols. Amanda and Dr. Karlfeldt discuss the Care Oncology “METRICS” drug set (including metformin, statins, doxycycline, and mebendazole), plus additional tools like ivermectin, fenbendazole, DCA, 2-DG, anti-inflammatories (aspirin/COX pathways), histamine blockers (cimetidine), and even PDE5 inhibitors like sildenafil/tadalafil—along with real cautions around dosing, contraindications, and interactions (including potential conflicts with immunotherapy). The conversation also ties metabolic therapy to the “press–pulse” concept and terrain-based care: ketogenic nutrition, inflammation reduction, oxygenation, and lifestyle foundations that strengthen the body while making cancer more vulnerable.
Whether you’re a patient, caregiver, or practitioner, this episode offers a grounded roadmap for thinking about integrative oncology without guesswork—using a “test, assess, address” mindset to build a strategy that evolves with labs, symptoms, treatment phases, and the individual.
Key Topics Covered (bulleted)